Verve Therapeutics Inc VERV

Healthcare Biotechnology

Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.

NDAQ:VERV - Post by User

Verve Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Dec 15, 2024 10:30am

34 Views

Post# 36363003

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigatio

Just In: $VERV Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach OutNEW YORK CITY, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and contin...VERV - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach Out

<< Previous

Bullboard Posts

Next >>

The top 5 Canadian small-cap AI stocks